Nuvectra Corporation announced preliminary Algovita® clinical data from its U.S. and EU multi-center, single-arm study demonstrating lead fracture and migration rates that were below industry average. The study data was presented by Robert Levy, MD, PhD, a board-certified neurological surgeon and member of Nuvectra’s Medical Advisory Board, at the International Neuromodulation Society (INS) 14th Annual World Congress in Sydney, Australia. The study, which is expected to enroll up to 120 patients and followed for 24 months, is designed to obtain real-world data on the Algovita® SCS system. Incidents of lead migrations and lead fractures at 1 month using the Algovita® SCS system were 5% and 0%, respectively; considerably lower than observed in industry literature (15.5% and 6.4%, respectively)1. The preliminary results are based on clinical outcomes for 75 patients up to approximately 7 months following permanent implantation at 18 clinical sites.